Seph Jensen, Chief Executive Officer of TearLab Corporation, graduated from Flagler College in 1994 with a double major in business administration and marketing, and a minor in advertising.
Seph started his career at ADP as the top sales person in the Orlando region. He then moved to Jacksonville to take a position with Warner Lambert. In 1996, Seph joined Alcon Laboratories where he embarked on a 17-year tenure serving in the pharmaceutical and medical device sectors. His roles included various commercial positions with focus in sales and marketing. His time with Alcon was split between local markets within the US and Japan along with Alcon headquarters in Fort Worth, TX. In 2012, Seph was promoted to the Head of Surgical Marketing, and was responsible for over $1.4 Billion in revenue.
In October 2013, Seph joined TearLab as the President and Chief Operating Officer and, as a seasoned leader with in-depth knowledge in the eye care category and a strong track record of delivering operational excellence and profitable growth, is poised to continue the company’s growth and success.
Benjamin Sullivan is co-founder and Chief Scientific Officer of TearLab Corp. He graduated from Boston University in 1997 with a B.S. in Biomedical Engineering (summa cum laude). He went on to research the effects of dry eye disease on molecular profiles of the tear film while at the Schepens Eye Research Institute affiliate of Harvard Medical School, prior to obtaining his Ph.D. in Bioengineering at the University of California, San Diego. Benjamin’s research on nanotechnology, microfluidics, molecular biology and clinical trial design has been widely cited in the peer-reviewed literature. His work has led to dozens of patents and helped create companies in the fields of ophthalmology, biotechnology and early cancer detection. His current work is focused on applied electromechanical phenomena at the nanoscale with an emphasis on improving specificity of diagnostic assays. Benjamin is also a co-founder and Director Lµbris LLC.
Wes Brazell, Chief Financial Officer of TearLab Corporation, graduated from Baylor University with a Bachelor of Business Administration degree in Accounting in 1988 and is a Certified Public Accountant since 1990.
Wes began his career with KPMG serving audit clients in the healthcare, manufacturing and financial sectors. In 1993 Wes joined Alcon Laboratories where he began a 21 year career in ophthalmology with finance roles of increasing responsibility including, financial analysis, investor relations, regional CFO roles in the United States and EURMEA (Europe, Middle East and Africa) and global business planning and analysis. In 2014, Wes moved from ophthalmology to become CFO of Academic Partnerships, a leading service provider in online higher education, where he led the global finance function of the company as well as other administrative areas.
In July 2015, Wes joined TearLab as Chief Financial Officer responsible for finance, strategic planning and managing interactions with the investment community. With his strong track record in financial leadership roles as well as in depth understanding of ophthalmology, Wes is ideally suited to contribute to the continued growth and success of the Company.
Dr Lemp is a corneal specialist; his major area of research interest is dry eye/ ocular surface disease. Over the last four decades he has published 209 peer-reviewed scientific articles, five books and served on national, international and government advisory boards. He organized and chaired the National Eye Institute/ Industry Workshop on Clinical Trials in Dry Eye; this report stands as the worldwide standard for the definition, classification and design of clinical trials for dry eye. He is one of four organizers of the follow up international Dry Eye Workshop (DEWS) the report of which was published in April 2007. His recent work is directed to further understanding instability of the tear film in dry eye states particularly the pathological events in the disease process and the development of new diagnostic and disease management modalities, most notably tear osmolarity.
After obtaining B.S.(1958) and M.D.(1962) degrees from Georgetown and residency training(1965-68) there, he served as a Fellow in Corneal Disease at the Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute(1968-70) where he authored the initial papers on qualitative disorders of the tear film while at these Harvard institutions. He has served as Professor and Chairman of the Department of Ophthalmology (1983-1992) at Georgetown University, as an officer and board member of many national and international ophthalmic organizations, member of the FDA Ophthalmic Devices Advisory Board, and NIH Study Sections and advisory committees. In 2001 he retired from his clinical practice with University Ophthalmic Consultants of Washington where he was president. He has continued his teaching and clinical research activities and is currently Clinical Professor of Ophthalmology at Georgetown and George Washington Universities, the founding Editor-in-Chief of The Ocular Surface, the international journal of review for ocular surface disease and serves as a scientific advisor to most of the major ophthalmic pharmaceutical companies. In addition, he is a scientific reviewer for all the ophthalmic journals and currently directs the clinical research program at TearLab Inc., where he is the Chief Medical officer. He has been Visiting Professor at 70 universities, delivered nine named lectures and in 1998 received the Castroviejo Medal, the highest international award for professional accomplishment in the field of corneal disease.
Michael Berg has over 25 years experience introducing new technology into the professional healthcare marketplace, through his own companies and as consultant to the industry. He is experienced in product development and acquisition, finance, manufacturing, marketing and strategic planning, domestic and international distribution, reimbursement and regulatory affairs. Michael, having studied and lived in Japan is an expert in Japanese regulatory and distribution strategies. As 50% joint-venture owner and President of HemoCue, Inc, Michael launched a blood hemoglobin point?of?care analyzer in the U.S. through a unique distribution model he created, the Independent Direct Distribution Organization. This model incorporated an educational approach to convert the healthcare profession from the prevailing spun microhematocrit technology, to a more expensive but accurate and safer hemoglobin test for the diagnosis of classic anemia. This distribution system provided all the advantages of a direct sales force at a fraction of the cost. Under this model, 13,000 HemoCue analyzers were sold into the market in the first 4 years of operation, with continued placement to date of 30,000+ instruments resulting in a business exceeding $50 million in annual revenue. Michael divested all interest in HemoCue, Inc. upon Mallinckrodt's acquisition of the parent company, HemoCue AB, in January 1991 for $100 million.
As a consultant to the industry, Michael has repeatedly formulated and implemented successful strategies to obtain CLIA Waiver categorization for point-of-care technology, solicited and obtained CPT coding through the American Medical Association process, and facilitated strong reimbursement for his clients through the Medicare (CMS) system. Focused on market development and physician education, Michael is experienced in the design and coordination of clinical studies, positioning products to meet clinical guidelines, evidence-based medicine and pay-for-performance criteria, and co-promotion with the pharmaceutical industry to link diagnosis and therapy. Michael received his BA from the University of Notre Dame and currently resides in Orange County California.
Sam Fakhoury joined TearLab Corporation in December 2014 as the Director of Quality and Compliance and was promoted to Vice President of Quality, Compliance and Supply Chain in August 2016. Mr. Fakhoury has more than 14 years of experience in Quality, Compliance, Manufacturing and Supply Chain, most recently with Johnson and Johnson. Mr. Fakhoury Holds a Degree in Electronic Engineering with a minor in Computer Science from the Southern California Institute of Technology and a Degree in Business Management with a minor in Supply Chain Management from the University of Phoenix.
Delano Ligu currently serves as Vice President of Information Technology for TearLab Corporation. Mr. Ligu has more then 16 years of experience in the Healthcare and Information Technology Verticals. Prior to obtaining his Master Degree in Biostatistics and Information Technology in Rumania, he graduated from University of Tirana, Faculty of Pharmacy and worked as a pharmacist for a number of years. Before joining TearLab Corporation, Mr. Ligu worked for OccuLogix Inc. and later TLC Vision Corporation as Director of Technical Services, being responsible for the entire Corporate IT Infrastructure and managing a team of talented IT professionals. He brings a great deal of experience in different areas such as system design, virtualization, networking, and security. Having worked primarily for Public Healthcare companies both in Canada and US, Mr. Ligu has been focused on system's security and compliance with HIPAA, PIPEDA, SOX and other privacy legislations that regulate the Healthcare Industry.
In this newly created position of Vice President of Business Development, Duane Morrison will focus on major accounts and doctor networks. Duane has 30 years of Sales, Business Development and General Management experience with proven entrepreneurial success.
In 2003, Mr. Morrison founded a private, high-tech mobile equipment leasing company (The Technology Source, Inc.) currently serving 500 eye care practitioners throughout 20 states by offering technology for the diagnosis and treatment of Glaucoma and Retinal disorders. Over the last 3 years, Mr. Morrison has gained valuable experience in the Dry Eye Disease marketplace by representing and providing consulting services, through The Technology Source, Inc., to a new pharmaceutical eye drop called FreshKote, manufactured by Focus Laboratories, Inc. Mr. Morrison stepped down as President of The Technology Source, Inc. to assume the role of Vice President of Sales with TearLab.
Prior to his work in the Glaucoma and Retina disease arena, Mr. Morrison held various senior positions with TLCVision (NASDAQ/TLCV, TSX/TLC) during a span of 9 years. Mr. Morrison was part of the 4 member development team that implemented the highly successful optometric co-management business model and strategic plan to bring Laser Vision Correction to the USA. Once Laser Centers opened, Mr. Morrison managed the sites as Regional General Manager and then joined the senior management team as National Director of Development responsible for all Business Development and smaller mergers, acquisitions and joint ventures.
Paul Smith currently serves as Vice President of International Markets for TearLab Corporation. Mr. Smith has more than 15 years of experience in sales and commercial leadership positions, most recently with Alcon, a division of Novartis. Mr. Smith joined TearLab from his position with Alcon as Global Manager for the company’s largest medical device franchise, representing over $1 billion in annual revenue. Over his 12 year career with Alcon, Mr. Smith held roles of increasing responsibility across pharmaceutical, consumer and medical device business unit operations where he led sales, marketing, strategic planning and portfolio management efforts both in the US and in global markets. Mr. Smith has extensive ophthalmic experience managing teams, building brands and commercializing products into a variety of international health systems. Mr. Smith earned his BA from the University of Central Florida and an MBA from the University of Florida.
Julie Speed currently serves as Vice President of Global Marketing for TearLab Corporation. Ms. Speed spent 15 years at Alcon, where her previous roles in global pharmaceutical and U.S. medical device franchises included managing the marketing for its intraocular lenses business, serving as a strategic advisor to its executive team, managing global brand strategies and tactics for its glaucoma franchise, and conducting primary and secondary market research for its glaucoma, anti-infective and otic brand teams. Ms. Speed earned her BS in Biomedical Science from Texas A&M University and an MBA from Texas Christian University. She also recently served as a Board Member of Ophthalmic Women Leaders (OWL).
Steve Zmina currently serves as Vice President of Manufacturing & Engineering. Steve has more than 28 years of product development experience in a number of high technology industries including medical, telecommunications, semiconductor, and industrial and high volume consumer products. His wide range of skills include product development, product marketing, manufacturing, and operations. Prior to TearLab Corporation, Steve was the Vice President of Product Development at Thermoscan, in San Diego, California, developing professional and consumer infrared ear thermometers. He has also been responsible for the development of a variety of high volume consumer products for Tandy Electronics. While at Tandy, his product development team developed over 40 new, high volume consumer products. He introduced digital signal processing into very low cost consumer products to significantly improve product performance and value to the customer. Steve has also held a number of other executive level positions in the semiconductor and power supply industries, developing products for the consumer and industrial markets. Steve has BSEE and MSEE degrees from Purdue University in semiconductor electronics.